Hoechst Pakistan Limited
Pharmaceutical company · 64 brands · 51 molecules
Ranked #11 of 39 companies in Agents Against Amoebiasis And Other Protozoal Diseases
Company overview
Hoechst Pakistan Limited is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 64 product registrations across 51 distinct molecules. Its portfolio is concentrated in Agents Against Amoebiasis And Other Protozoal Diseases and Anti-Infectives. DRAP has issued 1 alert involving its products.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Products by Hoechst
15 products matched in our catalogue — each with its observed price and DRAP approved ceiling.
Price ceiling age
DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.
Top molecules by brand count
Therapeutic classes
Conditions treated
Price band (DRAP official ceilings)
Regulatory record
1 alert in the DRAP feed we track.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Portfolio whitespace
Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.
Get the full profile for Hoechst
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included